doi:10.3390/biomedicines12091943 Bliddal H, Bays H, Czernichow S, et al
companies specialized in GLP-1s/endocrinology can also be potential acquisition targets for large pharmas with ambitions in such therapeutic areas Vertical : Collaborations with local active pharmaceutical ingredient/CDMO providers, injection pen manufacturers and injection needle suppliers can improve cost-efficiency and user experience With rising innovation and increasingly sophisticated stakeholder behavior, Chinas GLP-1 space has become both high potential and highly contested
Side effect profile, since a stronger restart response indicates successful resensitization
Integrated care matters here because the prescribers can actually adjust meds together rather than working at cross-purposes
The collection of information regarding the anti-cancer effects of drugs commonly used for other diseases could be of help in identifying potential repositionable compounds
Sitagliptin inhibits DPP4, the enzyme that breaks down incretin hormones
